Adjuvant therapy for endometrial cancer

Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological fa...

Full description

Saved in:
Bibliographic Details
Published inJournal of gynecologic oncology Vol. 25; no. 2; pp. 136 - 147
Main Authors Deleon, Maria C, Ammakkanavar, Natraj R, Matei, Daniela
Format Journal Article
LanguageEnglish
Published Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 01.04.2014
대한부인종양학회
Subjects
Review
산부인과학
Early stage
Endometrial cancer
Adjuvant therapy
Locally advanced
Risk stratification
Online AccessGet full text

Cover

More Information
Summary:Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
G704-001660.2014.25.2.009
ISSN:2005-0380
2005-0399
DOI:10.3802/jgo.2014.25.2.136